Statistics

Statistics

Total Visits

Views
AN OPEN-LABEL, MULTICENTER, RANDOMIZED, PHASE II STUDY OF CISPLATIN AND PEMETREXED WITH OR WITHOUT CIXUTUMUMAB (IMC-A12) AS FIRST-LINE THERAPY IN PATIENTS WITH ADVANCED NONSQUAMOUS NON-SMALL CELL LUNG CANCER 5

Total Visits Per Month

July 2019 August 2019 September 2019 October 2019 November 2019 December 2019 January 2020
AN OPEN-LABEL, MULTICENTER, RANDOMIZED, PHASE II STUDY OF CISPLATIN AND PEMETREXED WITH OR WITHOUT CIXUTUMUMAB (IMC-A12) AS FIRST-LINE THERAPY IN PATIENTS WITH ADVANCED NONSQUAMOUS NON-SMALL CELL LUNG CANCER 0 0 0 0 0 1 2

Top country views

Views

Top cities views

Views

Search DSpace



Browse

My Account

Statistics